Overview

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Enanta Pharmaceuticals
Criteria
Inclusion Criteria:

- Subjects must have chronic genotype-1 hepatitis C virus infection and plasma HCV-RNA ≥
105 IU/mL at the time of screening.

- Subjects must have chronic HCV infection as determined by any of the following:

- be anti-HCV (+) for at least 6 months per subject history or medical records

- an anti-HCV test, viral load, or genotype > 6 months ago

- In the setting of a recent positive anti-HCV test (< 6 months), liver biopsy
demonstrating chronicity

- Subjects must have IL-28b genotype "CC"

- Subjects must weigh at least 50 kg to participate in the study, and must have a body
mass index (BMI) within the range of 18 - 36 kg/m2. BMI = Body weight (kg) / [Height
(m)]2

Exclusion Criteria:

- Use of other investigational drugs at the time of enrollment, or within 5 half-lives
of enrollment, or within 30 days (for small molecules) whichever is longer; or longer
if required by local regulations.

- Previous treatment, including the use of any investigational agents, for the treatment
of HCV infection.

- Women of child bearing potential.

- Subjects with IL-28b genotype "CT or TT".

- ALT γ-GT, and AST must be below 5 x the upper limit of normal (ULN).

- Serum bilirubin must not exceed ULN.

- The PT (INR) must be within normal limits.

- If necessary, laboratory testing may be repeated on one occasion (as soon as possible)
prior to randomization, to rule out any laboratory error.

- Use of drugs that inhibit or induce CYP3A4.